This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. PBH, RYTM, PRGO, PTCT, CYTK, RNA, SRPT, RARE, AKRO, and ZLABShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Prestige Consumer Healthcare (PBH), Rhythm Pharmaceuticals (RYTM), Perrigo (PRGO), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Avidity Biosciences (RNA), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Zai Lab (ZLAB). These companies are all part of the "medical" sector. Edge Therapeutics vs. Prestige Consumer Healthcare Rhythm Pharmaceuticals Perrigo PTC Therapeutics Cytokinetics Avidity Biosciences Sarepta Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Zai Lab Edge Therapeutics (NASDAQ:EDGE) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Which has more volatility and risk, EDGE or PBH? Edge Therapeutics has a beta of 3.65, suggesting that its share price is 265% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Does the MarketBeat Community prefer EDGE or PBH? Prestige Consumer Healthcare received 321 more outperform votes than Edge Therapeutics when rated by MarketBeat users. Likewise, 70.14% of users gave Prestige Consumer Healthcare an outperform vote while only 66.79% of users gave Edge Therapeutics an outperform vote. CompanyUnderperformOutperformEdge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Prestige Consumer HealthcareOutperform Votes49870.14% Underperform Votes21229.86% Which has higher earnings and valuation, EDGE or PBH? Prestige Consumer Healthcare has higher revenue and earnings than Edge Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/APrestige Consumer Healthcare$1.14B3.73$209.34M$4.2920.04 Does the media refer more to EDGE or PBH? In the previous week, Prestige Consumer Healthcare had 8 more articles in the media than Edge Therapeutics. MarketBeat recorded 9 mentions for Prestige Consumer Healthcare and 1 mentions for Edge Therapeutics. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Edge Therapeutics' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edge Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate EDGE or PBH? Prestige Consumer Healthcare has a consensus price target of $93.33, suggesting a potential upside of 8.55%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prestige Consumer Healthcare 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in EDGE or PBH? 28.0% of Edge Therapeutics shares are held by institutional investors. Comparatively, 99.9% of Prestige Consumer Healthcare shares are held by institutional investors. 37.1% of Edge Therapeutics shares are held by insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is EDGE or PBH more profitable? Prestige Consumer Healthcare has a net margin of 19.13% compared to Edge Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 12.36% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Prestige Consumer Healthcare 19.13%12.36%6.39% SummaryPrestige Consumer Healthcare beats Edge Therapeutics on 13 of the 15 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.48B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.4026.7219.60Price / SalesN/A258.84395.56117.92Price / CashN/A65.8538.3234.62Price / Book39.596.416.764.50Net Income-$40.86M$143.73M$3.23B$248.40M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$37.610.0%N/A+956.7%$1.19BN/A0.00N/APBHPrestige Consumer Healthcare3.6841 of 5 stars$87.11+2.0%$93.33+7.1%+31.1%$4.32B$1.14B20.40540Positive NewsRYTMRhythm Pharmaceuticals3.9232 of 5 stars$60.18+5.1%$75.38+25.3%+63.9%$3.83B$136.86M-13.90140Positive NewsPRGOPerrigo4.6201 of 5 stars$26.30+1.1%$33.00+25.5%-10.0%$3.62B$4.34B-22.488,900Positive NewsPTCTPTC Therapeutics4.172 of 5 stars$45.31-3.1%$61.92+36.7%+17.8%$3.59B$1.77B-7.631,410Gap DownHigh Trading VolumeCYTKCytokinetics4.0292 of 5 stars$29.84-0.5%$74.44+149.5%-48.5%$3.56B$19.22M-5.55250RNAAvidity Biosciences1.9359 of 5 stars$28.97+2.0%$66.38+129.1%+4.0%$3.49B$10.90M-10.06190Gap DownSRPTSarepta Therapeutics4.7645 of 5 stars$35.27-1.3%$126.74+259.3%-69.8%$3.47B$2.23B28.22840Analyst ForecastGap DownHigh Trading VolumeRAREUltragenyx Pharmaceutical3.9401 of 5 stars$34.84+0.3%$90.93+161.0%-13.6%$3.29B$590.69M-5.501,310Gap UpAKROAkero Therapeutics3.7851 of 5 stars$39.96+5.5%$82.33+106.0%+138.9%$3.18BN/A-10.6630Gap DownZLABZai Lab2.5997 of 5 stars$28.75+2.2%$47.37+64.8%+61.2%$3.17B$418.33M-10.381,950 Related Companies and Tools Related Companies Prestige Consumer Healthcare Competitors Rhythm Pharmaceuticals Competitors Perrigo Competitors PTC Therapeutics Competitors Cytokinetics Competitors Avidity Biosciences Competitors Sarepta Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDGE Stock Free EDGE Stock Alerts